Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Type 2 diabetes is characterized by the body's inability to use insulin effectively. Insulin is a hormone that helps regulate metabolism properly. The condition is the most common type of ...

CF is an inherited disorder that causes the mucus in your body to be thick and sticky. It affects many organs and body ...

Allied Market Research published a report, titled, "Autoimmune Disease Testing Market by Product Type (Instruments and Consumables and ...

Africa's rapidly expanding cold chain market is projected to reach $14.85 billion by 2029, according to data from global ...

This theoretical study makes a useful contribution to our understanding of a subtype of type 2 diabetes – ketosis-prone diabetes mellitus (KPD) – with a potential impact on our broader understanding ...

Latin America Insulin Market was valued at US$ 2,855.1 million in 2022 and is projected to attain a valuation of US$ 3,857.50 million by 2031 at a CAGR of 3.4% During the Forecast Period 2023–2031.

Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 product SAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.